OBJECTIVES: Endometrial Cancer Health Outcomes Study in Argentina (ECHOS-A) is a real-world retrospective database study evaluating treatment patterns and health outcomes in patients with endometrial cancer (EC) affiliated to a health insurance plan in Argentina. This analysis assessed the risk of progression after first (1L) and second line (2L) of systemic therapy.

METHODS: Data from patients with EC from 2010–2019 were extracted from electronic medical charts. Index (proxy for diagnosis) was the first date of an EC-related health term or procedure/treatment. Progression was evaluated for patients that received 1L and 2L of systemic therapy. Time to progression was calculated from date of first drug dispensed in the line regimen until first subsequent treatment or death, whichever came first. Survival analysis (Kaplan-Meier) was performed considering total follow-up data. Cumulative risk of progression was presented from 1–5 years.

RESULTS: This study included 805 patients with EC. Mean follow-up was 33.6 months (standard deviation [SD] 31.8). One quarter (198; 24.6%) of these patients received ≥1L and 90 (11.2%) received ≥2 lines during follow-up. Amongst patients who received 1L, 45.5% also received 2L. In 1L, 130 events were recorded; 100 progressions to subsequent treatments, and 30 deaths. In 2L, 64 events were recorded (48 progressions and 16 deaths). Unadjusted mean (SD) and median time to progression in 1L were 14.1 (16.3) and 9.4 months, respectively, and 8.8 (8.3) and 6.4 months, respectively, in 2L. The 1–5-year adjusted cumulative risks of progression or death were 46.5%, 63.1%, 70.5%, 77.5% and 77.5%, respectively for 1L, and 65.0%, 77.9%, 81.9%, 86.2% and 86.2%, respectively, for 2L.

CONCLUSIONS: Systemically treated patients with EC demonstrated high progression rates in 1L and 2L. Almost half of 1L and two-thirds of 2L progressions happened during the first year of treatment, with a considerable decrease in time to progression across lines.